Clinical Trial

Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Object: To determine the effect of cerebrolysin on prolonged disorders of consciousness caused by hemorrhagic stroke. Participants: patients with prolonged disorders of consciousness due to severe traumatic brain injury Intervention: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously or 100 ml normal saline, days 4-17, once/day, IV Comparison: cerebrolysin group versus control group Outcome: Coma Recovery Scale-revised, FDG-PET signal
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-06-08; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Recruiting 2026-05-06
Trial Details
NCT Number NCT04427241
Lead Sponsor Konkuk University Medical Center
Collaborators: Ever Neuro Pharma GmbH
Conditions Disorder of Consciousness, Hemorrhagic Stroke
Enrollment 12 participants
Start Date 2023-06-01
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-11